Aa
Infergen and VX-950 Trial Warning
Spoke to Cedars-Sinai hosp. in L.A. yesterday where they are holding the VX-950 trials for non-responders. Just wanted to pass on what they told me to everyone who is interested in entering that trial. If you have been on Infergen, you will be excluded from the trial for some unknown reason.
This is the case with me, as my last failed treatment was with Riba and Infergen. They are going to try and get a waiver so I can enter the trial. Just a warning to all that it is their current policy. Again, no explanation why. Talk to your doctor if you are anticipating Infergen as a treatment...
Magnum
My apologies...wahy was i thinkn you wre talkn bout the BOC,,,,,you were talkin teleprevir....finally brain fog has hit me.
Good for you!! So glad to hear you are eligible. It's been a long wait for you....I hope they get you started soon.
Will look forward to hearing good news from you.
Will look forward to hearing good news from you.
Little confused, are you talking about telaprevir as in your first post? Or has boceprevir decided to take you?
Either way both great drugs, congrats
Either way both great drugs, congrats
MAG....after what you went tru....this BOC will be a walk in the freakn park
are you in this new trial....
Next-Generation HCV Protease Inhibitor SCH 900518
As part of its long-term commitment to hepatitis C therapy, Schering-Plough also is developing SCH 900518 ("518"), a next-generation HCV protease inhibitor. A Phase IIa study with 518, known as the NEXT-1 study, is currently ongoing. The company said that 518 has been shown to be 10 times more potent in-vitro than other protease inhibitors currently in Phase III development and has the potential for once daily dosing. 518 also has shown decreased emergence of resistance in vitro. Given its pharmacokinetic (PK) profile, the company anticipates that 518 may be active against some HCV strains that are resistant to other protease inhibitors. Phase I proof of concept studies with 518 in treatment-naive patients and those who failed prior treatment, both as monotherapy and in combination with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.
Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting
http://www.medicalnewstoday.com/articles/130622.php
Next-Generation HCV Protease Inhibitor SCH 900518
As part of its long-term commitment to hepatitis C therapy, Schering-Plough also is developing SCH 900518 ("518"), a next-generation HCV protease inhibitor. A Phase IIa study with 518, known as the NEXT-1 study, is currently ongoing. The company said that 518 has been shown to be 10 times more potent in-vitro than other protease inhibitors currently in Phase III development and has the potential for once daily dosing. 518 also has shown decreased emergence of resistance in vitro. Given its pharmacokinetic (PK) profile, the company anticipates that 518 may be active against some HCV strains that are resistant to other protease inhibitors. Phase I proof of concept studies with 518 in treatment-naive patients and those who failed prior treatment, both as monotherapy and in combination with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.
Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting
http://www.medicalnewstoday.com/articles/130622.php
Congrats! Looks like the presentence paid off. Man I give you kudos for having to go through this again and anyone else faced with treatment more than once.
jasper
jasper
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
